Mural Oncology plc (NASDAQ:MURA) Shares Sold by FNY Investment Advisers LLC

FNY Investment Advisers LLC trimmed its position in shares of Mural Oncology plc (NASDAQ:MURA) by 25.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 15,000 shares of the company’s stock after selling 5,000 shares during the period. FNY Investment Advisers LLC’s holdings in Mural Oncology were worth $48,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new position in Mural Oncology in the 2nd quarter valued at about $5,300,000. Primecap Management Co. CA purchased a new stake in Mural Oncology during the 2nd quarter worth approximately $740,000. Renaissance Technologies LLC acquired a new position in shares of Mural Oncology in the 2nd quarter valued at approximately $729,000. Squarepoint Ops LLC purchased a new position in shares of Mural Oncology during the 2nd quarter valued at approximately $526,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Mural Oncology during the third quarter worth approximately $340,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Insider Buying and Selling

In related news, CFO Adam D. Cutler sold 7,421 shares of the company’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total transaction of $25,305.61. Following the completion of the transaction, the chief financial officer now directly owns 71,438 shares in the company, valued at $243,603.58. This represents a 9.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on MURA shares. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Mural Oncology in a research note on Monday, November 11th. Raymond James initiated coverage on Mural Oncology in a report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 price objective for the company.

Mural Oncology Stock Performance

Shares of NASDAQ:MURA opened at $3.69 on Thursday. The company’s fifty day moving average is $3.57 and its two-hundred day moving average is $3.40. Mural Oncology plc has a 1-year low of $2.87 and a 1-year high of $5.62. The stock has a market capitalization of $62.80 million, a price-to-earnings ratio of -0.40 and a beta of 3.83.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.